HK Stock Market Move | Hansoh Pharma (03692) rose more than 3%. The Phase III clinical study of HS-20093 for the treatment of small cell lung cancer has achieved its primary endpoint.

HANSOH PHARMA (03692) rose more than 3%, as of the time of publication, it rose 3.38% to HKD 32.94 with a trading volume of 127 million Hong Kong dollars. On the news front, on July 10, HANSOH PHARMA announced that the group's independently developed B7-H3 targeted antibody-drug conjugate (ADC) HS20093 has achieved the primary endpoint of overall survival (OS) in the pivotal Phase III clinical trial (ARTEMIS-008) in patients with small cell lung cancer (SCLC) progressing or relapsing after platinum-based therapy. At the prespecified analysis time, HS-20093 showed statistically and clinically significant improvement in OS compared to topotecan, with consistent benefits observed in secondary clinical endpoints including progression-free survival (PFS). The safety profile was consistent with previous study results, with no new safety signals identified. Based on these positive results, the group will initiate discussions with regulatory agencies and begin preparations for a new drug application in China. Detailed data from the ARTEMIS-008 study is expected to be presented at an upcoming international oncology academic conference.